CLRB · Cellectar Biosciences, Inc. · Executive Compensation
$1.49
+0.09 (+6.43%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates it will be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable future. Accordingly, the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.”View the 10-Q filed Aug 13, 2026
Market Cap
$13.33M
Shares
9.45M
Volume · Oct 8
169.7K
Avg daily vol (3M)
63.36K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| James Caruso | President and Chief Executive Officer | $3,042,750 |
| James V. Caruso | President and Chief Executive Officer | $3,042,750 |
| Jarrod Longcor | Chief Operating Officer | $1,830,000 |
| Chad Kolean | Chief Financial Officer | $1,223,400 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| James V. Caruso | President and Chief Executive Officer | $1,965,140 |
| James Caruso | President and Chief Executive Officer | $1,965,140 |
| Jarrod Longcor | Chief Operating Officer | $1,362,560 |
| Chad Kolean | Chief Financial Officer | $1,108,960 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| James V. Caruso | President and Chief Executive Officer | $1,463,172 |
| James Caruso | President and Chief Executive Officer | $1,463,172 |
| Jarrod Longcor | Chief Operating Officer | $831,755 |
| Chad Kolean | Chief Financial Officer | $461,643 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| James Caruso | President and Chief Executive Officer | $2,151,250 |
| James V. Caruso | President and Chief Executive Officer | $2,151,250 |
| Jarrod Longcor | Chief Operating Officer | $891,446 |
| Dov Elefant | Former Vice President and Chief Financial Officer | $838,150 |
| John E. Friend II | Former Vice President and Chief Medical Officer | $706,549 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| James V. Caruso | President and Chief Executive Officer | $1,016,240 |
| James Caruso | President and Chief Executive Officer | $1,016,240 |
| Igor Grachev | M.D., Ph.D. | $584,076 |
| Jarrod Longcor | Chief Operating Officer and Former Chief Business Officer | $574,507 |
| Dov Elefant | Former Vice President and Chief Financial Officer | $471,860 |
| John E. Friend II | Former Vice President and Chief Medical Officer | $386,310 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| James V. Caruso | President and Chief Executive Officer | $934,460 |
| James Caruso | President and Chief Executive Officer | $934,460 |
| Jarrod Longcor | Chief Business Officer | $539,303 |
| Dov Elefant | Vice President and Chief Financial Officer | $312,437 |
| Charles T. Bernhardt | — | $187,313 |
| Brian Posner | Former Vice President and Chief Financial Officer | $63,219 |
| Former Chief Medical | Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| James V. Caruso | President and Chief Executive Officer | $770,012 |
| James Caruso | President and Chief Executive Officer | $770,012 |
| Jarrod Longcor | Chief Business Officer | $477,888 |
| Brian Posner | Former Vice President and Chief Financial Officer | $417,376 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Douglas J. Swirsky | Class III director | Appointed | 2026-07-10 |
| Andrew Gu | Class III director | Appointed | 2026-07-10 |
| Andrew Gu | Class III director | Appointed | 2026-05-18 |
| John Neis | Class I director | Appointed | 2024-06-14 |
| Asher Chanan-Khan, M.B.B.S., M.D. | Class I director | Appointed | 2024-06-14 |
| Douglas J. Swirsky | Class III director | Appointed | 2023-06-29 |
| Stefan D. Loren, Ph.D. | Class III director | Appointed | 2023-06-29 |